Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631733 · ClinicalTrials.gov registry record · Phase 1
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02631733: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02631733 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02631733, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Ferumoxytol
- PROCEDURE Magnetic Resonance Imaging
- OTHER Laboratory Biomarker Analysis
- DRUG Irinotecan Sucrosofate
- DRUG Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02631733
The ClinicalTrials.gov registry entry for NCT02631733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ferumoxytol is the first listed.
NCT02631733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02631733 about?
NCT02631733 is a clinical study titled "Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors". This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02631733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2017-05-31. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT02631733?
The interventions under investigation include: Ferumoxytol (DRUG), Magnetic Resonance Imaging (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Irinotecan Sucrosofate (DRUG), Veliparib (DRUG).
Who is sponsoring clinical trial NCT02631733?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.